Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07333885 · ClinicalTrials.gov registry record · NA
Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)
A NA study of Glycemic Response and Menopause Symptoms, sponsored by Phynova Group.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07333885: Recruiting NA study of Glycemic Response and Menopause Symptoms, sponsored by Phynova Group.
NCT07333885 is a NA study of Glycemic Response and Menopause Symptoms that is actively recruiting participants, run by Phynova Group. The registered enrollment target is 120 participants, below the 288-participant average among 4 other Glycemic Response trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07333885, a NA study of Glycemic Response and Menopause Symptoms, is actively recruiting participants, sponsored by Phynova Group.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.
Primary Outcome
Postprandial glycemic response measured as 0-120-minute incremental area under the curve (iAUC) from interstitial glucose readings captured by Dexcom Stelo CGM.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Reducose® (Mulberry leaf extract)
Study Locations (1)
California
- People Science - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT07333885 shows while recruiting
NCT07333885 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 288-participant average among 4 other Glycemic Response trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Glycemic Response appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07333885 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07333885 about?
NCT07333885 is a clinical study titled "Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)". The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is meas...
What is the current status of trial NCT07333885?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-12-12. Estimated completion is 2026-08.
What conditions does trial NCT07333885 study?
This clinical trial studies the following conditions: Glycemic Response, Menopause Symptoms.
What interventions are being tested in trial NCT07333885?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Reducose® (Mulberry leaf extract) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07333885?
This trial is sponsored by Phynova Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07333885 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glycemic Response
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Impact of Fruit Juice, Fruit Juice With Pomace, or Whole Fruit on Glycemic Response
COMPLETED · NA
-
Effects of Concord Grape Juice Alone on Glycemia, Appetite and Cognitive Function in Healthy Adults
COMPLETED · NA
-
The Breakfast Study
COMPLETED · NA
-
PRediction Of Glycemic RESponse Study
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI